Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

Galiè, 2015, Eur Respir J, 46, 903, 10.1183/13993003.01032-2015 McGoon, 2013, Pulmonary arterial hypertension: epidemiology and registries, J Am Coll Cardiol, 62, D51, 10.1016/j.jacc.2013.10.023 Taichman, 2005, Health-related quality of life in patients with pulmonary arterial hypertension, Respir Res, 6, 92, 10.1186/1465-9921-6-92 Farber, 2015, Five-year outcomes of patients enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension (PAH) disease management (REVEAL), Chest, 148, 1043, 10.1378/chest.15-0300 Humbert, 2010, Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension, Eur Respir J, 36, 549, 10.1183/09031936.00057010 McLaughlin, 2013, Treatment goals of pulmonary hypertension, J Am Coll Cardiol, 62, D73, 10.1016/j.jacc.2013.10.034 Nickel, 2012, The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension, Eur Respir J, 39, 589, 10.1183/09031936.00092311 Sitbon, 2015, Validation of two predictive models for survival in pulmonary arterial hypertension, Eur Respir J, 46, 152, 10.1183/09031936.00004414 Simonneau, 2016, Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial, Lancet Respir Med, 10.1016/S2213-2600(16)30022-4 Stasch, 2013, Soluble guanylate cyclase stimulators in pulmonary hypertension, Handb Exp Pharmacol, 218, 279, 10.1007/978-3-662-45805-1_12 Ghofrani, 2013, Riociguat for the treatment of pulmonary arterial hypertension, N Engl J Med, 369, 330, 10.1056/NEJMoa1209655 Rubin, 2015, Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2), Eur Respir J, 45, 1303, 10.1183/09031936.00090614 Langleben, 2015, Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study, J Heart Lung Transplant, 34, 338, 10.1016/j.healun.2014.12.001 Gabler, 2012, Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials, Circulation, 126, 349, 10.1161/CIRCULATIONAHA.112.105890 Mathai, 2012, The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension, Am J Respir Crit Care Med, 186, 428, 10.1164/rccm.201203-0480OC Simonneau, 2015, Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2), Eur Respir J, 45, 1293, 10.1183/09031936.00087114 Mathai, 2015, Health outcome assessment in pulmonary arterial hypertension patients treated with riociguat: 2-year results from the PATENT-2 long term extension study, Am J Respir Crit Care Med, 191, A4777 Benza, 2011, Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension, J Heart Lung Transplant, 30, 1327, 10.1016/j.healun.2011.08.019 Provencher, 2006, Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension, Eur Heart J, 27, 589, 10.1093/eurheartj/ehi728 Farber, 2015, Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance, J Heart Lung Transplant, 34, 362, 10.1016/j.healun.2014.08.020 Macchia, 2007, A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology, Am Heart J, 153, 1037, 10.1016/j.ahj.2007.02.037 Macchia, 2010, Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed, Am Heart J, 159, 245, 10.1016/j.ahj.2009.11.028 Savarese, 2012, Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials, J Am Coll Cardiol, 60, 1192, 10.1016/j.jacc.2012.01.083 Benza, 2011, Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials, J Heart Lung Transplant, 30, 982, 10.1016/j.healun.2011.03.011 Barst, 2003, Beraprost therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 41, 2119, 10.1016/S0735-1097(03)00463-7 Barst, 2006, Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil, Eur Respir J, 28, 1195, 10.1183/09031936.06.00044406 Oudiz, 2009, Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension, J Am Coll Cardiol, 54, 1971, 10.1016/j.jacc.2009.07.033 Rubin, 2011, Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2, Chest, 140, 1274, 10.1378/chest.10-0969 McLaughlin, 2005, Survival with first-line bosentan in patients with primary pulmonary hypertension, Eur Respir J, 25, 244, 10.1183/09031936.05.00054804 Pulido, 2013, Macitentan and morbidity and mortality in pulmonary arterial hypertension, N Engl J Med, 369, 809, 10.1056/NEJMoa1213917 McLaughlin, 2006, Survival in patients with pulmonary arterial hypertension treated with first-line bosentan, Eur J Clin Invest, 36, 10, 10.1111/j.1365-2362.2006.01688.x Sitbon, 2015, Selexipag for the treatment of pulmonary arterial hypertension, N Engl J Med, 373, 2522, 10.1056/NEJMoa1503184 Simonneau, 2015, Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN, Eur Respir J, 46, 1711, 10.1183/13993003.00364-2015 Bayer Pharma Bayer Pharma